DATE: February 5, 2004 SHEET _1_ of _1_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
	7283.US.01	Not assigned yet
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S)	
	T. Kolasa, et al.	
(Use several sheets if necessary)	FILING DATE	GROUP
	February 5, 2004	Not assigned yet
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO
EB	B1	1,384,523	02/19/75	Great Britain				
EB	B2	1,378,080	12/18/74	Great Britain				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EB	C1	Andersson, K. et al., "Physiology of penile erection," Physiol. Rev. 75:191-236 (195)
	C2	Hrib, N., "The dopamine D4 receptor: a controversial therapeutic target", Drugs of the Future: 25:587-611 (2000)
	C3	DeGroat, W. et al., "Neural Control of Penile Erection, in : Nervous control of urogenital system," Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)
	C4	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," Urology 56:130-135 (2000)
	C5	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," Trends Pharmacol Sci 20:118-124 (1998)
	C6	Missale, C. et al. "Dopamine receptors: from structure to function," Physiol Rev 78:189-225 (1998)
	C7	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," Urologic Clinics of North America, vol. 22:879-886 (1995)
	C8	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," Curr Opinion CPNS Invest Drugs, 2:283-302 (2000)
	C9	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999)
	C10	Primus, R. et al., "Localization and characterization of dopamine D_4 binding sites in rat and human brain by use of the novel D_4 receptor-selective ligand [^{3}H]NGD 94-1," J. Pharmacol Exp. Ther 282:1020-1027 (1997)
	C11	Melis M., et al., "Dopamine and sexual behavior", Neuroscience and Behavioral Reviews 19: 19-38 (1995)
	C12	Suzuki, M. et al., "D_3 dopamine receptor mRNA is widely express in human brain," Brian Res 779:58-74 (1998)
	C13	Vallone, D. et al., "Structure and function of dopamine receptors," Neurosci Biobehav. Rev. 24:125-132 (2000)
	C14	Chen F., et al., "Effects of dopamine, apomorphine, gamma hydroxybutiruc acid, haloperidol, and pimozide on reflex bradicardia in rats", J. Pharmacol. Exp. Therap. 214:427-432 (1980)
	C15	Hahn R.A. et al., "Primate cardiovascular responses mediated by dopaminergic receptors: effects of N,N-dihydrodopamine and LY171555" J. Pharmacol Exp. Therap. 229:132-138 (1984)
	C16	Bendele et al., "Anti-inflammatory activity of pergolide, a dopamine receptor agonist", J. Pharmacol Exp. Therap. 259:169-175 (1991)
	C17	Lissoni et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer-related hyperprolactinemia", Neuroendocrinology Letters 21:405-408 (2000)
	C18	Martinez-Esparza et al., "New 1-Aryl-3-(4-arylpiperazin-1-yl)propane derivatives with dual action at 5-HT_{1A} Serotonin Receptors and Serotonin transporter, as a new class of antidepressant" J. Med. Chem. 44:418-428 (2001)

EXAMINER E Bernhardt DATE CONSIDERED 4/15/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)